Eli Lilly and Company (NYSE:LLY) Sets New 1-Year High – Should You Buy?

Eli Lilly and Company (NYSE:LLY) shares hit a new 52-week high on Monday . The stock traded as high as $1,075.72 and last traded at $1,057.6320, with a volume of 497525 shares changing hands. The stock had previously closed at $1,059.70.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Guggenheim restated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, BMO Capital Markets boosted their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,047.50.

Eli Lilly and Company Stock Performance

The company has a market cap of $1.01 trillion, a P/E ratio of 69.52, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a fifty day simple moving average of $855.89 and a two-hundred day simple moving average of $787.81.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. bought a new position in Eli Lilly and Company in the 3rd quarter worth $83,979,000. Bell Investment Advisors Inc increased its position in Eli Lilly and Company by 4.0% in the third quarter. Bell Investment Advisors Inc now owns 336 shares of the company’s stock worth $256,000 after buying an additional 13 shares in the last quarter. Maple Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. Maple Capital Management Inc. now owns 46,921 shares of the company’s stock worth $35,801,000 after buying an additional 154 shares during the period. Oarsman Capital Inc. raised its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Oarsman Capital Inc. now owns 1,957 shares of the company’s stock worth $1,493,000 after buying an additional 68 shares during the period. Finally, Ariadne Wealth Management LP lifted its position in shares of Eli Lilly and Company by 2.3% during the 3rd quarter. Ariadne Wealth Management LP now owns 1,156 shares of the company’s stock valued at $882,000 after buying an additional 26 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.